Salim Syed
Stock Analyst at Mizuho
(2.28)
# 2,692
Out of 5,112 analysts
77
Total ratings
41.94%
Success rate
0.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $97.63 | +23.94% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $32.58 | +22.77% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.77 | +690.96% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $59.82 | +40.42% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $172.10 | -1.80% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $326.01 | -14.11% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $121.36 | -3.59% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $16.34 | +34.64% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $43.06 | +278.54% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $17.18 | +4.77% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $16.00 | +112.50% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $54.74 | +80.85% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $74.02 | -28.40% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.35 | +1,455.56% | 5 | Nov 16, 2022 |
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $97.63
Upside: +23.94%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $32.58
Upside: +22.77%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.77
Upside: +690.96%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $59.82
Upside: +40.42%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $172.10
Upside: -1.80%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $326.01
Upside: -14.11%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $121.36
Upside: -3.59%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $16.34
Upside: +34.64%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $43.06
Upside: +278.54%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $17.18
Upside: +4.77%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $16.00
Upside: +112.50%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $54.74
Upside: +80.85%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $74.02
Upside: -28.40%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.35
Upside: +1,455.56%